Veterinary Anesthesia Pharmacokinetics: A Guide to Inhaled and Intravenous Agents

Partial pressure plays a key role in the uptake and distribution of inhaled anaesthetics:

• Definition: Partial pressure represents the force driving a gas into solution and its movement across compartments (lungs, blood, and brain).
• Higher partial pressure: Increases alveolar concentration and accelerates drug absorption into the bloodstream and brain.
• Equilibration: The brain’s anaesthetic concentration rises when the alveolar partial pressure stabilizes.

The solubility of an anaesthetic agent in blood directly affects its speed of onset and recovery:

• Low blood-gas solubility (e.g., desflurane, sevoflurane): Leads to rapid induction and recovery.
• High blood-gas solubility (e.g., halothane): Causes slower induction and prolonged recovery times.
• Henry’s Law: Describes the relationship between gas solubility and its partial pressure in solution.

Atmospheric pressure affects the partial pressure of inhaled anaesthetic agents:

• At high altitudes (lower atmospheric pressure): Partial pressure of gases is reduced, slowing anaesthetic absorption into the blood.
• At sea level (normal atmospheric pressure): Uptake is more predictable, and agents function as expected.
• Clinical relevance: Anaesthetic vaporizers must be calibrated properly when used at high altitudes.

The anaesthetic gas concentration is expressed in multiple ways to describe its effect on the body:

• Volume-to-volume ratio (%): Describes the fraction of an inhaled gas within a mixture (e.g., 2% isoflurane).
• Partial pressure: Determines how much anaesthetic dissolves in blood and tissues, affecting onset and potency.
• Molar concentration: Less commonly used but describes gas molecules per unit volume.

The uptake of inhaled anaesthetics is influenced by three primary factors:

• Alveolar ventilation: Increased ventilation speeds up drug delivery to the lungs, enhancing uptake.
• Solubility: Low blood-gas solubility results in faster induction, while high solubility slows uptake.
• Cardiac output: Higher cardiac output increases the distribution of the anaesthetic, delaying its effect on the brain.

Blood-gas solubility influences how quickly anaesthetic effects are achieved and reversed:

• Low blood-gas solubility (e.g., desflurane, sevoflurane) → Rapid induction and recovery.
• High blood-gas solubility (e.g., halothane) → Slower induction and prolonged recovery.
• This is because highly soluble agents remain in the blood longer before reaching the brain.

The speed of recovery from inhaled anaesthesia depends on:

• Exhalation: Most inhaled anaesthetics are eliminated unchanged through the lungs.
• Blood-gas solubility: Low solubility agents (e.g., sevoflurane) are exhaled faster, leading to quicker recovery.
• Tissue uptake: The amount of anaesthetic absorbed by body tissues also affects elimination speed.

Rapid elimination of inhaled anaesthetics improves patient safety by:

• Reducing prolonged sedation: Faster clearance lowers the risk of post-operative respiratory depression.
• Enhancing controlled recovery: Patients regain consciousness more predictably.
• Minimizing drug accumulation: Reducing anaesthetic hangover effects, particularly in long procedures.

Volatility and potency are distinct properties of inhaled anaesthetics:

• Volatility: Describes how easily an anaesthetic converts from liquid to gas (e.g., isoflurane is more volatile than halothane).
• Potency: Measured by Minimum Alveolar Concentration (MAC)—the lower the MAC, the more potent the anaesthetic.
• Clinical application: A more potent anaesthetic (low MAC) requires lower concentrations to achieve the desired effect.

MAC is an important measure of anaesthetic potency:

• Definition: The alveolar concentration needed to prevent movement in 50% of subjects under surgical stimulation.
• Higher MAC: This means the anaesthetic is less potent (e.g., nitrous oxide).
• Lower MAC: This means the anaesthetic is more potent (e.g., isoflurane).
• Clinical relevance: Helps in determining appropriate dosing for maintaining surgical anaesthesia.

The vaporizer is a critical component in inhalation anaesthesia:

• Function: Converts liquid anaesthetic into vapour and precisely controls its concentration.
• Types: Variable-bypass vaporizers (e.g., for isoflurane) and electronically controlled vaporizers.
• Importance: Ensures consistent drug delivery and prevents excessive or inadequate anaesthesia.

The breathing system directly influences anaesthetic uptake and elimination:

• Rebreathing vs. Non-rebreathing Circuits:
• Rebreathing circuits (e.g., circle systems): Allow gas recirculation, affecting anaesthetic washout.
• Non-rebreathing circuits: Provide fresh gas flow with each breath, allowing for quicker changes in anaesthetic depth.
• Dead Space and Resistance: Larger dead space may slow gas exchange, impacting induction and recovery speed.

The lungs are responsible for the uptake and elimination of inhaled anaesthetics:

• Gas Exchange: Anaesthetic agents diffuse across the alveolar membrane into the bloodstream.
• Exhalation: Most inhaled anaesthetics are eliminated unchanged via the lungs, making exhalation the primary route of clearance.
• Minimal Metabolism: Unlike injectable agents, inhaled anaesthetics undergo little hepatic metabolism.

Cardiac output plays a major role in the speed of anaesthetic onset and elimination:

• High cardiac output: Increases blood flow to peripheral tissues, diluting the anaesthetic concentration in the brain and delaying induction.
• Low cardiac output: Reduces peripheral distribution, leading to a more rapid onset of anaesthesia.
• Clinical impact: Patients with circulatory shock may experience faster anaesthetic effects due to reduced perfusion to other tissues.

Patients with respiratory compromise require special considerations for inhalation anaesthesia:

• Increased ventilation: Helps compensate for reduced alveolar exchange and ensures adequate anaesthetic uptake.
• Oxygen supplementation: Maintains arterial oxygen levels and prevents hypoxia.
• Careful monitoring: Detects any respiratory depression caused by the anaesthetic agent.

The volume of distribution (Vd) is a key concept in drug pharmacokinetics:

• Low Vd: The drug remains mostly in the bloodstream (e.g., neuromuscular blockers).
• High Vd: The drug extensively distributes into tissues (e.g., propofol).
• Clinical relevance: High Vd anaesthetics remain in fat and muscle, affecting duration and recovery time.

Total elimination clearance (ClE) refers to the rate at which a drug is removed from the body:

• High clearance (e.g., propofol): This leads to rapid drug elimination, resulting in shorter anaesthetic effects.
• Low clearance (e.g., thiopental): Prolongs anaesthetic duration, as the drug remains in circulation longer.
• Organs involved: Liver (hepatic metabolism) and kidneys (renal excretion) play a major role in clearance.

Elimination half-life (t½β) is the time it takes for a drug’s plasma concentration to decrease by 50%:

• Short half-life (e.g., propofol): Leads to faster recovery post-anaesthesia.
• Long half-life (e.g., diazepam): Causes prolonged sedation due to slower drug elimination.
• Clinical significance: Helps determine drug dosing intervals to maintain stable anaesthesia levels.

The one-compartment model is the simplest way to describe drug distribution:

• Assumption: The drug equilibrates instantly throughout the entire body.
• Example: Water-soluble drugs that remain mostly in plasma.
• Limitation: Many anaesthetic drugs follow more complex distribution patterns.

A two-compartment model describes drug movement into:

• Central compartment: Blood and highly perfused organs where rapid initial distribution occurs.
• Peripheral compartment: Fat, muscle, and less perfused tissues where slower redistribution and elimination take place.

Clinical impact: This model explains why some anaesthetics (e.g., thiopental) initially cause deep sedation but later redistribute to fat, leading to delayed recovery.

The multicompartment model applies to drugs with complex distribution and elimination profiles:

• Initial rapid uptake: Into well-perfused organs (brain, liver, kidneys).
• Secondary redistribution: The drug moves into fat and muscle, prolonging its effects.
• Slow elimination: Some drugs remain in tissues for extended periods (e.g., fentanyl, diazepam).

Compartmental models are essential for understanding intravenous anaesthetic pharmacokinetics:

• Predicting drug action: Helps estimate how quickly a drug takes effect and how long it lasts.
• Dosing strategies: Ensures correct drug administration to maintain anaesthesia.
• Managing side effects: Prevents drug accumulation in fat, which can delay recovery.

Target-Controlled Infusion (TCI) is an advanced method of delivering intravenous anaesthesia:

• Automated drug delivery: Uses pharmacokinetic models to calculate and adjust the infusion rate in real time.
• Improved precision: Reduces fluctuations in drug levels, preventing underdosing or overdose.
• Commonly used drugs: Propofol and remifentanil are frequently administered using TCI.

Both methods are used for delivering intravenous anaesthesia:

• Fixed-rate infusions: Maintain a constant drug administration rate but require careful monitoring to avoid accumulation.
• Bolus dosing: Provides intermittent injections based on patient response, leading to fluctuations in anaesthetic depth.
• Clinical considerations: Fixed infusions offer more stability, while bolus dosing may be used for short procedures or initial induction.

Several factors must be considered when administering intravenous anaesthetic drugs:

• Metabolism: Patients with liver or kidney disease may clear anaesthetic agents more slowly, requiring dose adjustments.
• Age: Geriatric patients may have altered drug sensitivity, necessitating lower doses.
• Body composition: Fat-soluble drugs distribute differently in lean vs. obese patients, affecting duration and recovery.

Patients with renal insufficiency may have reduced clearance of drugs, leading to prolonged anaesthetic effects. Proper adjustments include:

• Lowering the dose: To prevent excessive sedation.
• Increasing the dosing interval: Allows more time for drug metabolism and elimination.
• Monitoring for delayed recovery: Impaired renal excretion may contribute to prolonged effects.

Delayed recovery in inhalation anaesthesia may be due to slow elimination caused by:

• High blood-gas solubility: Anaesthetics with high solubility (e.g., halothane) take longer to clear from tissues.
• Inadequate ventilation: Hypoventilation reduces the exhalation of anaesthetic gas, prolonging sedation.
• Large body mass: Anaesthetics accumulate in fat and muscle, extending recovery time.

Prolonged unconsciousness and respiratory depression may indicate drug accumulation or delayed metabolism in the patient:

• Stopping the infusion: Prevents further drug buildup and allows recovery.
• Providing oxygen support: Maintains adequate oxygenation during respiratory depression.
• Assessing liver function: Propofol is metabolized hepatically, and some species (e.g., cats) have slower clearance rates.